ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A
Co-founded with renowned immunologist Professor Caetano Reis e Sousa of the Francis Crick Institute
First UK-based ATP portfolio company
NEW YORK and LONDON, December 7, 2021—ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. (“Adendra”), a company that will discover and develop treatments for cancers and autoimmune diseases by applying new insights into regulation of adaptive immune responses by dendritic cells. Adendra is funded with a $53 (£40) million Series A investment from ATP and founded by ATP as a spin-out of breakthrough biology conducted at the Francis Crick Institute in London in the lab of immunologist Caetano Reis e Sousa, D.Phil., whose research on ways in which dendritic cells orchestrate immune responses to cell death has been published in leading scientific journals.
